A scoping review and network meta-analysis for efficacy and safety of glaucoma medication in Japanese patients
Purpose To investigate the efficacy and safety of glaucoma medication in Japanese patients, network meta-analysis (NMA) of an intraocular pressure(IOP) reduction, adverse reaction rates and conjunctival congestion rates of major glaucoma drugs used in clinical practice in Japan were conducted using...
Gespeichert in:
| Veröffentlicht in: | Japanese journal of ophthalmology 2020-03, Vol.64 (2), p.103-113 |
|---|---|
| Hauptverfasser: | , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 113 |
|---|---|
| container_issue | 2 |
| container_start_page | 103 |
| container_title | Japanese journal of ophthalmology |
| container_volume | 64 |
| creator | Inoue, Kenji Ishida, Kyoko Tomita, Goji Noma, Hisashi |
| description | Purpose
To investigate the efficacy and safety of glaucoma medication in Japanese patients, network meta-analysis (NMA) of an intraocular pressure(IOP) reduction, adverse reaction rates and conjunctival congestion rates of major glaucoma drugs used in clinical practice in Japan were conducted using the new drug application (NDA) data.
Study design
Scoping network meta-analysis.
Methods
Out of all clinical trials in the interview forms of major glaucoma drugs approved in Japan as of July 2015, active-control clinical trials with Japanese patients were identified through screening with specific criteria. The details of IOP reduction, adverse reaction rates and conjunctival hyperemia rates of the trials were collected from published articles, package inserts, interview forms and Summary basis of approval made by Japan Pharmaceutical and Medical Devices Agency (PMDA). The mean difference in IOP reduction, adverse reaction rates, and conjunctival hyperemia rates of eligible trials were assessed using NMA as referenced to those of timolol maleate 0.5%.
Results
Eleven multicenter trials of ten medications in total, (five prostaglandin (PG) analogs, three β-blockers, one α-1 blocker, and one α-2 stimulator) were selected. The mean difference in IOP reduction in mmHg with 95% confidence intervals were as follows: bimatoprost −3.00 (−3.71; −2.29), tafluprost −2.45 (−3.65; −1.25), travoprost −2.35 (−3.41; −1.29), and latanoprost −2.05 (−2.72; −1.38). The highest IOP reduction was achieved by PG analogs. Adverse reaction rates and conjunctival hyperemia rates were significantly larger with PG analogs than with other medications.
Conclusion
The efficacy and safety of glaucoma medications were assessed by NMA as reference to those of timolol maleate 0.5% in Japanese patients. PG analogs were the most efficacious in reducing IOP. However, PG analogs were also associated with higher rates of adverse reactions and conjunctival hyperemia. |
| doi_str_mv | 10.1007/s10384-019-00708-0 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_2371946056</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2371946056</sourcerecordid><originalsourceid>FETCH-LOGICAL-c399t-3e9150fa18454d7a619d9071c24a464316c1c12052bfc67cf782df78f38f22b43</originalsourceid><addsrcrecordid>eNp9kE1PAyEQhonRaK3-AQ-GxDM6Ayy7ezTGz5h40TOhLDSrLayw1fTfi9aPm5chwzzvO5mXkCOEUwSozzKCaCQDbFlpoWGwRSaoUDDOpdomEwCOrMKq2iP7OT8DgOSC75I9waFVwPmEhHOabRz6MKfJvfXunZrQ0eDG95he6NKNhplgFuvcZ-pjos773hq7_sKy8W5c0-jpfGFWNi5NUXRlPvYx0D7QOzOY4LKjQ_lyYcwHZMebRXaH3--UPF1dPl7csPuH69uL83tmRduOTLgWK_AGG1nJrjYK266FGi2XRiopUFm0yKHiM29VbX3d8K4ULxrP-UyKKTnZ-A4pvq5cHvVzXKVySNZc1NhKBZUqFN9QNsWck_N6SP3SpLVG0J8R603EukSsvyLWUETH39arWbn2V_KTaQHEBshlFOYu_e3-x_YDVxmGmw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2371946056</pqid></control><display><type>article</type><title>A scoping review and network meta-analysis for efficacy and safety of glaucoma medication in Japanese patients</title><source>MEDLINE</source><source>SpringerLink Journals - AutoHoldings</source><creator>Inoue, Kenji ; Ishida, Kyoko ; Tomita, Goji ; Noma, Hisashi</creator><creatorcontrib>Inoue, Kenji ; Ishida, Kyoko ; Tomita, Goji ; Noma, Hisashi</creatorcontrib><description>Purpose
To investigate the efficacy and safety of glaucoma medication in Japanese patients, network meta-analysis (NMA) of an intraocular pressure(IOP) reduction, adverse reaction rates and conjunctival congestion rates of major glaucoma drugs used in clinical practice in Japan were conducted using the new drug application (NDA) data.
Study design
Scoping network meta-analysis.
Methods
Out of all clinical trials in the interview forms of major glaucoma drugs approved in Japan as of July 2015, active-control clinical trials with Japanese patients were identified through screening with specific criteria. The details of IOP reduction, adverse reaction rates and conjunctival hyperemia rates of the trials were collected from published articles, package inserts, interview forms and Summary basis of approval made by Japan Pharmaceutical and Medical Devices Agency (PMDA). The mean difference in IOP reduction, adverse reaction rates, and conjunctival hyperemia rates of eligible trials were assessed using NMA as referenced to those of timolol maleate 0.5%.
Results
Eleven multicenter trials of ten medications in total, (five prostaglandin (PG) analogs, three β-blockers, one α-1 blocker, and one α-2 stimulator) were selected. The mean difference in IOP reduction in mmHg with 95% confidence intervals were as follows: bimatoprost −3.00 (−3.71; −2.29), tafluprost −2.45 (−3.65; −1.25), travoprost −2.35 (−3.41; −1.29), and latanoprost −2.05 (−2.72; −1.38). The highest IOP reduction was achieved by PG analogs. Adverse reaction rates and conjunctival hyperemia rates were significantly larger with PG analogs than with other medications.
Conclusion
The efficacy and safety of glaucoma medications were assessed by NMA as reference to those of timolol maleate 0.5% in Japanese patients. PG analogs were the most efficacious in reducing IOP. However, PG analogs were also associated with higher rates of adverse reactions and conjunctival hyperemia.</description><identifier>ISSN: 0021-5155</identifier><identifier>EISSN: 1613-2246</identifier><identifier>DOI: 10.1007/s10384-019-00708-0</identifier><identifier>PMID: 32096022</identifier><language>eng</language><publisher>Tokyo: Springer Japan</publisher><subject>Active control ; Analogs ; Antihypertensive Agents - therapeutic use ; Clinical Investigation ; Clinical trials ; Confidence intervals ; Drug development ; Drugs ; Glaucoma ; Glaucoma - drug therapy ; Glaucoma - epidemiology ; Glaucoma - physiopathology ; Humans ; Hyperemia ; Inserts ; Intraocular pressure ; Intraocular Pressure - drug effects ; Intraocular Pressure - physiology ; Japan - epidemiology ; Medical equipment ; Medicine ; Medicine & Public Health ; Meta-analysis ; Morbidity - trends ; Network Meta-Analysis ; Ophthalmology ; Patients ; Reduction ; Safety ; Side effects ; Stimulators ; Timolol</subject><ispartof>Japanese journal of ophthalmology, 2020-03, Vol.64 (2), p.103-113</ispartof><rights>Japanese Ophthalmological Society 2020</rights><rights>2020© Japanese Ophthalmological Society 2020</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c399t-3e9150fa18454d7a619d9071c24a464316c1c12052bfc67cf782df78f38f22b43</citedby><cites>FETCH-LOGICAL-c399t-3e9150fa18454d7a619d9071c24a464316c1c12052bfc67cf782df78f38f22b43</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s10384-019-00708-0$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s10384-019-00708-0$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,776,780,27901,27902,41464,42533,51294</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/32096022$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Inoue, Kenji</creatorcontrib><creatorcontrib>Ishida, Kyoko</creatorcontrib><creatorcontrib>Tomita, Goji</creatorcontrib><creatorcontrib>Noma, Hisashi</creatorcontrib><title>A scoping review and network meta-analysis for efficacy and safety of glaucoma medication in Japanese patients</title><title>Japanese journal of ophthalmology</title><addtitle>Jpn J Ophthalmol</addtitle><addtitle>Jpn J Ophthalmol</addtitle><description>Purpose
To investigate the efficacy and safety of glaucoma medication in Japanese patients, network meta-analysis (NMA) of an intraocular pressure(IOP) reduction, adverse reaction rates and conjunctival congestion rates of major glaucoma drugs used in clinical practice in Japan were conducted using the new drug application (NDA) data.
Study design
Scoping network meta-analysis.
Methods
Out of all clinical trials in the interview forms of major glaucoma drugs approved in Japan as of July 2015, active-control clinical trials with Japanese patients were identified through screening with specific criteria. The details of IOP reduction, adverse reaction rates and conjunctival hyperemia rates of the trials were collected from published articles, package inserts, interview forms and Summary basis of approval made by Japan Pharmaceutical and Medical Devices Agency (PMDA). The mean difference in IOP reduction, adverse reaction rates, and conjunctival hyperemia rates of eligible trials were assessed using NMA as referenced to those of timolol maleate 0.5%.
Results
Eleven multicenter trials of ten medications in total, (five prostaglandin (PG) analogs, three β-blockers, one α-1 blocker, and one α-2 stimulator) were selected. The mean difference in IOP reduction in mmHg with 95% confidence intervals were as follows: bimatoprost −3.00 (−3.71; −2.29), tafluprost −2.45 (−3.65; −1.25), travoprost −2.35 (−3.41; −1.29), and latanoprost −2.05 (−2.72; −1.38). The highest IOP reduction was achieved by PG analogs. Adverse reaction rates and conjunctival hyperemia rates were significantly larger with PG analogs than with other medications.
Conclusion
The efficacy and safety of glaucoma medications were assessed by NMA as reference to those of timolol maleate 0.5% in Japanese patients. PG analogs were the most efficacious in reducing IOP. However, PG analogs were also associated with higher rates of adverse reactions and conjunctival hyperemia.</description><subject>Active control</subject><subject>Analogs</subject><subject>Antihypertensive Agents - therapeutic use</subject><subject>Clinical Investigation</subject><subject>Clinical trials</subject><subject>Confidence intervals</subject><subject>Drug development</subject><subject>Drugs</subject><subject>Glaucoma</subject><subject>Glaucoma - drug therapy</subject><subject>Glaucoma - epidemiology</subject><subject>Glaucoma - physiopathology</subject><subject>Humans</subject><subject>Hyperemia</subject><subject>Inserts</subject><subject>Intraocular pressure</subject><subject>Intraocular Pressure - drug effects</subject><subject>Intraocular Pressure - physiology</subject><subject>Japan - epidemiology</subject><subject>Medical equipment</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Meta-analysis</subject><subject>Morbidity - trends</subject><subject>Network Meta-Analysis</subject><subject>Ophthalmology</subject><subject>Patients</subject><subject>Reduction</subject><subject>Safety</subject><subject>Side effects</subject><subject>Stimulators</subject><subject>Timolol</subject><issn>0021-5155</issn><issn>1613-2246</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kE1PAyEQhonRaK3-AQ-GxDM6Ayy7ezTGz5h40TOhLDSrLayw1fTfi9aPm5chwzzvO5mXkCOEUwSozzKCaCQDbFlpoWGwRSaoUDDOpdomEwCOrMKq2iP7OT8DgOSC75I9waFVwPmEhHOabRz6MKfJvfXunZrQ0eDG95he6NKNhplgFuvcZ-pjos773hq7_sKy8W5c0-jpfGFWNi5NUXRlPvYx0D7QOzOY4LKjQ_lyYcwHZMebRXaH3--UPF1dPl7csPuH69uL83tmRduOTLgWK_AGG1nJrjYK266FGi2XRiopUFm0yKHiM29VbX3d8K4ULxrP-UyKKTnZ-A4pvq5cHvVzXKVySNZc1NhKBZUqFN9QNsWck_N6SP3SpLVG0J8R603EukSsvyLWUETH39arWbn2V_KTaQHEBshlFOYu_e3-x_YDVxmGmw</recordid><startdate>20200301</startdate><enddate>20200301</enddate><creator>Inoue, Kenji</creator><creator>Ishida, Kyoko</creator><creator>Tomita, Goji</creator><creator>Noma, Hisashi</creator><general>Springer Japan</general><general>Springer Nature B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QL</scope><scope>7T7</scope><scope>7U9</scope><scope>8FD</scope><scope>C1K</scope><scope>FR3</scope><scope>H94</scope><scope>K9.</scope><scope>M7N</scope><scope>P64</scope></search><sort><creationdate>20200301</creationdate><title>A scoping review and network meta-analysis for efficacy and safety of glaucoma medication in Japanese patients</title><author>Inoue, Kenji ; Ishida, Kyoko ; Tomita, Goji ; Noma, Hisashi</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c399t-3e9150fa18454d7a619d9071c24a464316c1c12052bfc67cf782df78f38f22b43</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Active control</topic><topic>Analogs</topic><topic>Antihypertensive Agents - therapeutic use</topic><topic>Clinical Investigation</topic><topic>Clinical trials</topic><topic>Confidence intervals</topic><topic>Drug development</topic><topic>Drugs</topic><topic>Glaucoma</topic><topic>Glaucoma - drug therapy</topic><topic>Glaucoma - epidemiology</topic><topic>Glaucoma - physiopathology</topic><topic>Humans</topic><topic>Hyperemia</topic><topic>Inserts</topic><topic>Intraocular pressure</topic><topic>Intraocular Pressure - drug effects</topic><topic>Intraocular Pressure - physiology</topic><topic>Japan - epidemiology</topic><topic>Medical equipment</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Meta-analysis</topic><topic>Morbidity - trends</topic><topic>Network Meta-Analysis</topic><topic>Ophthalmology</topic><topic>Patients</topic><topic>Reduction</topic><topic>Safety</topic><topic>Side effects</topic><topic>Stimulators</topic><topic>Timolol</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Inoue, Kenji</creatorcontrib><creatorcontrib>Ishida, Kyoko</creatorcontrib><creatorcontrib>Tomita, Goji</creatorcontrib><creatorcontrib>Noma, Hisashi</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Industrial and Applied Microbiology Abstracts (Microbiology A)</collection><collection>Virology and AIDS Abstracts</collection><collection>Technology Research Database</collection><collection>Environmental Sciences and Pollution Management</collection><collection>Engineering Research Database</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biotechnology and BioEngineering Abstracts</collection><jtitle>Japanese journal of ophthalmology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Inoue, Kenji</au><au>Ishida, Kyoko</au><au>Tomita, Goji</au><au>Noma, Hisashi</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>A scoping review and network meta-analysis for efficacy and safety of glaucoma medication in Japanese patients</atitle><jtitle>Japanese journal of ophthalmology</jtitle><stitle>Jpn J Ophthalmol</stitle><addtitle>Jpn J Ophthalmol</addtitle><date>2020-03-01</date><risdate>2020</risdate><volume>64</volume><issue>2</issue><spage>103</spage><epage>113</epage><pages>103-113</pages><issn>0021-5155</issn><eissn>1613-2246</eissn><abstract>Purpose
To investigate the efficacy and safety of glaucoma medication in Japanese patients, network meta-analysis (NMA) of an intraocular pressure(IOP) reduction, adverse reaction rates and conjunctival congestion rates of major glaucoma drugs used in clinical practice in Japan were conducted using the new drug application (NDA) data.
Study design
Scoping network meta-analysis.
Methods
Out of all clinical trials in the interview forms of major glaucoma drugs approved in Japan as of July 2015, active-control clinical trials with Japanese patients were identified through screening with specific criteria. The details of IOP reduction, adverse reaction rates and conjunctival hyperemia rates of the trials were collected from published articles, package inserts, interview forms and Summary basis of approval made by Japan Pharmaceutical and Medical Devices Agency (PMDA). The mean difference in IOP reduction, adverse reaction rates, and conjunctival hyperemia rates of eligible trials were assessed using NMA as referenced to those of timolol maleate 0.5%.
Results
Eleven multicenter trials of ten medications in total, (five prostaglandin (PG) analogs, three β-blockers, one α-1 blocker, and one α-2 stimulator) were selected. The mean difference in IOP reduction in mmHg with 95% confidence intervals were as follows: bimatoprost −3.00 (−3.71; −2.29), tafluprost −2.45 (−3.65; −1.25), travoprost −2.35 (−3.41; −1.29), and latanoprost −2.05 (−2.72; −1.38). The highest IOP reduction was achieved by PG analogs. Adverse reaction rates and conjunctival hyperemia rates were significantly larger with PG analogs than with other medications.
Conclusion
The efficacy and safety of glaucoma medications were assessed by NMA as reference to those of timolol maleate 0.5% in Japanese patients. PG analogs were the most efficacious in reducing IOP. However, PG analogs were also associated with higher rates of adverse reactions and conjunctival hyperemia.</abstract><cop>Tokyo</cop><pub>Springer Japan</pub><pmid>32096022</pmid><doi>10.1007/s10384-019-00708-0</doi><tpages>11</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0021-5155 |
| ispartof | Japanese journal of ophthalmology, 2020-03, Vol.64 (2), p.103-113 |
| issn | 0021-5155 1613-2246 |
| language | eng |
| recordid | cdi_proquest_journals_2371946056 |
| source | MEDLINE; SpringerLink Journals - AutoHoldings |
| subjects | Active control Analogs Antihypertensive Agents - therapeutic use Clinical Investigation Clinical trials Confidence intervals Drug development Drugs Glaucoma Glaucoma - drug therapy Glaucoma - epidemiology Glaucoma - physiopathology Humans Hyperemia Inserts Intraocular pressure Intraocular Pressure - drug effects Intraocular Pressure - physiology Japan - epidemiology Medical equipment Medicine Medicine & Public Health Meta-analysis Morbidity - trends Network Meta-Analysis Ophthalmology Patients Reduction Safety Side effects Stimulators Timolol |
| title | A scoping review and network meta-analysis for efficacy and safety of glaucoma medication in Japanese patients |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-29T14%3A46%3A35IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=A%20scoping%20review%20and%20network%20meta-analysis%20for%20efficacy%20and%20safety%20of%20glaucoma%20medication%20in%20Japanese%20patients&rft.jtitle=Japanese%20journal%20of%20ophthalmology&rft.au=Inoue,%20Kenji&rft.date=2020-03-01&rft.volume=64&rft.issue=2&rft.spage=103&rft.epage=113&rft.pages=103-113&rft.issn=0021-5155&rft.eissn=1613-2246&rft_id=info:doi/10.1007/s10384-019-00708-0&rft_dat=%3Cproquest_cross%3E2371946056%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2371946056&rft_id=info:pmid/32096022&rfr_iscdi=true |